Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.63 |
| ▸ | ALPI | P09923 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | XIAP | P98170 | 1/20 | 0.63 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11499279 | 1.00 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL18286579 | 0.84 | SLC7A5 (0.62) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL31501285 | 0.84 | SLC7A5 (0.79) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28268747 | 0.84 | SLC7A5 (0.79) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL9295400 | 0.83 | SLC7A5 (0.66) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL28345408 | 0.83 | SLC7A5 (0.66) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL19193059 | 0.83 | SLC7A5 (0.66) | SLC7A5ALPIPKMPTGS1XIAP | |
| D-Phenylalanine SCHEMBL30582493 | 0.82 | SLC7A5 (0.76) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL1692013 | 0.81 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL623613 | 0.80 | ALPI (0.49) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017042162-A1 | PLANTS WITH REDUCED ASPARAGINE CONTENT | PHILIP MORRIS PRODUCTS S.A. (CH) | 2017-03-16 | — | — | WO | disclosed |
| US-20100125069-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | RIGEL PHARMACEUTICALS INC. (US) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125069-A1 | Methods of Treating or Preventing Autoimmune Diseases with 2,4-Pyrimidinediamine Compounds | SSB, TYMS, TPMT | SLC7A5 1506/4885ALPI 1680/4885PKM 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.